PersonGen BioTherapeutics is developing CD19-CART cells targeting CD19+ B-cell malignancies, particularly in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and other hematological malignancies. The market for CAR T-cell therapies is expanding, with significant competition from established players like Novartis and Gilead. The unique focus on CD19, a well-characterized target in B-cell cancers, positions PersonGen favorably, but the company must navigate regulatory pathways and demonstrate robust clinical efficacy to secure market share. The potential for Ig supplementation in long-term therapy may also influence treatment adoption and reimbursement strategies.